Clinical Trial Update: Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating AGN-190584 in presbyopia subjects has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Presbyopia

Drugs mentioned

• AGN-190584

Snippet

Sponsor: Gordon Schanzlin New Vision | Conditions: Presbyopia | Phase 4 | Status: WITHDRAWN